Hip Fractures

JAMA Pub Date : 2026-07-16 DOI:10.1001/jama.2026.11895
Fjola Johannesdottir, Jimmie E. Roberts, Douglas P. Kiel, Joy N. Tsai
{"title":"Hip Fractures","authors":"Fjola Johannesdottir, Jimmie E. Roberts, Douglas P. Kiel, Joy N. Tsai","doi":"10.1001/jama.2026.11895","DOIUrl":null,"url":null,"abstract":"Importance More than 14.2 million people worldwide and 280 000 in the US experience a hip fracture each year. The median 1-year mortality rate after a hip fracture is 22% and approximately 42% to 71% of patients regain their prefracture level of basic activities of daily living within 6 months. Observations Hip fractures are classified as intracapsular or extracapsular and most commonly occur after a fall. Intracapsular hip fractures include femoral neck (34%) and femoral head (rare). Extracapsular fractures consist of intertrochanteric (48%) and subtrochanteric fractures (5.8%). In the US, between 2008 and 2017, hip fractures were associated with 1-year mortality rates of 26.9% among men and 18.5% among women. Older age is a major risk factor for hip fracture, with a hazard ratio of 1.35 (95% CI, 1.25-1.47) per 5-year increase in age. Women have higher incidence of hip fractures than men due to accelerated bone loss after menopause and higher incidence of falls. Other risk factors for hip fractures include low bone mineral density (bone density of 1 SD or below that of healthy young adults measured by dual-energy x-ray absorptiometry), prior fracture, and factors contributing to falls, such as weak muscles, poor visual acuity, and smoking. Surgery for hip fracture typically consists of hip joint replacement or hip joint stabilization, using embedded hardware (open reduction and internal fixation). Patients with hip fracture benefit from physical therapy and fall reduction strategies, such as muscle-strengthening exercises and modifying medications associated with increased fall risk, such as antidepressants, and should be treated with antiresorptive medications, such as bisphosphonates (alendronate, zoledronic acid) or denosumab to prevent subsequent fracture. To prevent a hip fracture, patients with vertebral osteoporosis at the spine may require anabolic therapy, such as teriparatide, abaloparatide, or romosozumab, before starting an antiresorptive. Hip fractures may lead to mobility limitations; declines in physical, emotional, and social functioning; and reduced health-related quality of life. Conclusions and Relevance Hip fractures are common among older people and are associated with a 1-year mortality rate of 22% and with reduced mobility and quality of life. Surgical repair for hip fracture typically consists of joint replacement or open reduction and internal fixation. Hip fracture treatment also includes physical therapy, fall reduction strategies, and medications to protect against fracture, such as bisphosphonates; denosumab; or anabolic drugs, such as parathyroid hormone analogues or romosozumab.","PeriodicalId":518009,"journal":{"name":"JAMA","volume":"251 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2026-07-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"JAMA","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1001/jama.2026.11895","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Importance More than 14.2 million people worldwide and 280 000 in the US experience a hip fracture each year. The median 1-year mortality rate after a hip fracture is 22% and approximately 42% to 71% of patients regain their prefracture level of basic activities of daily living within 6 months. Observations Hip fractures are classified as intracapsular or extracapsular and most commonly occur after a fall. Intracapsular hip fractures include femoral neck (34%) and femoral head (rare). Extracapsular fractures consist of intertrochanteric (48%) and subtrochanteric fractures (5.8%). In the US, between 2008 and 2017, hip fractures were associated with 1-year mortality rates of 26.9% among men and 18.5% among women. Older age is a major risk factor for hip fracture, with a hazard ratio of 1.35 (95% CI, 1.25-1.47) per 5-year increase in age. Women have higher incidence of hip fractures than men due to accelerated bone loss after menopause and higher incidence of falls. Other risk factors for hip fractures include low bone mineral density (bone density of 1 SD or below that of healthy young adults measured by dual-energy x-ray absorptiometry), prior fracture, and factors contributing to falls, such as weak muscles, poor visual acuity, and smoking. Surgery for hip fracture typically consists of hip joint replacement or hip joint stabilization, using embedded hardware (open reduction and internal fixation). Patients with hip fracture benefit from physical therapy and fall reduction strategies, such as muscle-strengthening exercises and modifying medications associated with increased fall risk, such as antidepressants, and should be treated with antiresorptive medications, such as bisphosphonates (alendronate, zoledronic acid) or denosumab to prevent subsequent fracture. To prevent a hip fracture, patients with vertebral osteoporosis at the spine may require anabolic therapy, such as teriparatide, abaloparatide, or romosozumab, before starting an antiresorptive. Hip fractures may lead to mobility limitations; declines in physical, emotional, and social functioning; and reduced health-related quality of life. Conclusions and Relevance Hip fractures are common among older people and are associated with a 1-year mortality rate of 22% and with reduced mobility and quality of life. Surgical repair for hip fracture typically consists of joint replacement or open reduction and internal fixation. Hip fracture treatment also includes physical therapy, fall reduction strategies, and medications to protect against fracture, such as bisphosphonates; denosumab; or anabolic drugs, such as parathyroid hormone analogues or romosozumab.
髋部骨折
每年全球有超过1420万人髋部骨折,美国有28万人髋部骨折。髋部骨折后1年的死亡率中位数为22%,约42%至71%的患者在6个月内恢复到骨折前的基本日常生活活动水平。髋部骨折分为囊内骨折和囊外骨折,最常见于跌倒后。髋关节囊内骨折包括股骨颈(34%)和股骨头(罕见)。囊外骨折包括转子间骨折(48%)和转子下骨折(5.8%)。在美国,2008年至2017年期间,髋部骨折与男性的1年死亡率为26.9%,女性为18.5%。高龄是髋部骨折的主要危险因素,每5年年龄增加的风险比为1.35 (95% CI, 1.25-1.47)。女性髋部骨折的发生率比男性高,因为绝经后骨质流失加快,摔倒的发生率也更高。髋部骨折的其他危险因素包括低骨密度(通过双能x线吸收仪测量的健康年轻人的骨密度为1sd或以下)、先前的骨折以及导致跌倒的因素,如肌肉无力、视力差和吸烟。髋部骨折的手术通常包括髋关节置换或髋关节稳定,使用嵌入式硬件(切开复位和内固定)。髋部骨折患者受益于物理治疗和减少跌倒的策略,如肌肉强化运动和与增加跌倒风险相关的修改药物,如抗抑郁药,并应使用抗吸收药物,如双膦酸盐(阿仑膦酸,唑来膦酸)或地诺单抗,以防止后续骨折。为了预防髋部骨折,脊柱椎体骨质疏松症患者可能需要在开始抗吸收治疗前进行合成代谢治疗,如特立帕肽、阿巴帕肽或罗莫索单抗。髋部骨折可能导致活动受限;身体、情感和社会功能下降;与健康相关的生活质量降低。髋部骨折在老年人中很常见,1年死亡率为22%,并伴有活动能力和生活质量下降。髋部骨折的手术修复通常包括关节置换术或切开复位内固定。髋部骨折治疗还包括物理治疗、减少跌倒策略和预防骨折的药物治疗,如双磷酸盐;denosumab;或合成代谢药物,如甲状旁腺激素类似物或romosozumab。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书